ArticleBMC bioinformatics2026
NAP: an open source pipeline for cross-domain microbiome profiling using Nanopore sequencing-derived amplicon data.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanopore sequencing offers a cost-effective and portable platform for microbiome analysis, but amplicon-based approaches remain limited by higher sequencing error rates and a lack of workflows tailored to mixed domain ribosomal RNA profiling. While short-read technologies dominate microbial community analysis, their portability and flexibility are constrained. There is therefore a need for robust pipelines designed specifically for cross-domain Nanopore amplicon data.
resultsWe introduce the Nanopore sequencing-based Amplicon Pipeline (NAP; https://github.com/Luke-B-Jones/NAP ), an open source workflow optimised for flexible mixed domain primer sets such as 515Y/926R. NAP combines dynamic quality filtering and base muting, chimera removal, centroid generation, BLAST-based taxonomic classification, hierarchical consensus correction, RAW-read reassignment, blank-informed decontamination, and domain-aware post-processing to produce curated genus level and species level abundance tables. Validation against logarithmic and gut commercial mock communities showed strongest performance at genus level, with reliable recovery above ca. 1% relative abundance and reproducible community reconstruction under Bray-Curtis, Jaccard, agreement plot, and Bland-Altman analyses. Internal benchmarking showed that dynamic filtering and base muting provided the most defensible balance between read quality, retained depth, and taxonomic fidelity across heterogeneous inputs, avoiding the sensitivity loss of fixed filtering approaches, and the reduced fidelity of overly permissive or aggressively masked alternatives. The consensus step substantially reduced raw centroid-based false positive burden in biological mocks by 82.9% at genus level and 78.8% at species level, while decontamination removed 7.00 ± 2.68 species level contaminant hits per replicate and adjusted a further 9.83 ± 6.49 abundances. Direct benchmarking against QIIME2 and Kraken2/Bracken showed that NAP best preserved expected community structure, with markedly fewer unexpected genera and stronger species level behaviour under the tested conditions. Synthetic ground truth benchmarking across richness/evenness panels, high similarity marker conflicts, and low abundance titrations further supported robustness: NAP produced no unsupported genus level calls, achieved genus level precision, recall, and F1-score of 1.000, 0.939, and 0.967 across community structure panels, and showed complete detection from ca. 1% relative abundance under default filtering. Residual species level errors were concentrated in high identity marker conflicts rather than arbitrary taxonomic assignments.
conclusionsNAP provides a reproducible, flexible, domain-aware consensus workflow for cross-domain Nanopore amplicon profiling, with strongest support at genus level and competitive species level performance for well resolved taxa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.